Harbinger Health develops a two-tier blood testing model that detects early-stage cancer by identifying biological markers present before tumor formation. This approach addresses the limitations of current cancer detection methods, making early screening accessible and affordable for all individuals.
Funding
$190M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer detection methods often identify the disease only after it has progressed, limiting treatment options and impacting survival rates. Existing screening tools may also be inaccessible or unaffordable for many individuals, leading to disparities in early detection.
Solution
Harbinger Health is developing blood-based tests designed to detect cancer in its earliest stages, before tumor formation and the onset of symptoms. By identifying unique biological markers present in the pre-disease state, the company aims to enable earlier therapeutic interventions and improve patient outcomes. Their approach combines insights into the biology of cancer's origin with artificial intelligence and advanced screening technologies. The goal is to make cancer screening more accessible and affordable, particularly for those who have historically faced barriers to healthcare and prevention.
Target Audience
The primary target audience includes individuals at risk of developing cancer, healthcare providers seeking to improve early detection rates, and organizations focused on expanding access to cancer screening.
Features
- Proprietary blood tests that identify biological programs present in the earliest forms of cancer
- Utilizes artificial intelligence to analyze complex biological data and improve detection accuracy
- Focuses on detecting cancer before the development of tumors and onset of symptoms
- Aims to provide accessible and affordable cancer screening for all individuals